| 3.615 0.015 (0.42%) | 12-15 15:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.61 | 1-year : | 5.38 |
| Resists | First : | 3.95 | Second : | 4.61 |
| Pivot price | 3.62 |
|||
| Supports | First : | 3.23 |
Second : | 2.79 |
| MAs | MA(5) : | 3.67 |
MA(20) : | 3.6 |
| MA(100) : | 2.97 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 51.7 |
D(3) : | 59.2 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 6.21 | Low : | 1.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MRVI ] has closed above bottom band by 47.4%. Bollinger Bands are 39.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.74 - 3.77 | 3.77 - 3.79 |
| Low: | 3.46 - 3.48 | 3.48 - 3.5 |
| Close: | 3.57 - 3.61 | 3.61 - 3.64 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.
Mon, 15 Dec 2025
MRVI: Wells Fargo Maintains Rating and Raises Price Target | MRV - GuruFocus
Fri, 12 Dec 2025
Maravai LifeSciences Holdings, Inc. $MRVI Stock Holdings Boosted by Immersion Corp - MarketBeat
Thu, 11 Dec 2025
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Wed, 10 Dec 2025
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Up Following Insider Buying Activity - MarketBeat
Tue, 09 Dec 2025
Maravai Lifesciences (MRVI) Director Acquires 100K Shares - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 145 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 90.5 (%) |
| Shares Short | 12,280 (K) |
| Shares Short P.Month | 12,990 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.7 |
| Profit Margin | -62.9 % |
| Operating Margin | -80.7 % |
| Return on Assets (ttm) | -7.8 % |
| Return on Equity (ttm) | -41 % |
| Qtrly Rev. Growth | -39.8 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 1.32 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -4.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.12 |
| Price to Sales | 2.72 |
| Price to Cash Flow | -10.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|